



Investors should consider diversified exposure to innovation leaders in AI, power infrastructure, and longevity. (UBS)

CIO expects global AI spending to hit USD 375bn this year

14 August 2025, 17:38 UTC, written by UBS Editorial Team

CIO expects structural growth ideas—AI, Power and resources, and Longevity—to deliver attractive returns in the years ahead. In AI, diversified and balanced exposure across the value chain, including laggards, should capture accelerating adoption and monetization.

CIO expects power and resources to continue to benefit from surging electricity demand. And longevity is supported by demographic shifts and rapid innovation.

Trade, fiscal, and economic growth uncertainties may drive summer volatility.

- Trade uncertainty remains elevated, with open questions about US sectoral tariffs and legal challenges to them.
- US fiscal concerns are elevated following the passage of the One Big Beautiful Bill Act.
- Weaker US labor reports may signal a slower GDP growth outlook for the US in the second half of the year.

But AI, power and resources, and longevity should continue to drive long-term returns.

- We expect global Al spending to hit USD 375bn this year. For 2026, we anticipate another 33% growth to USD 500bn.
- Power and resources companies should benefit from accelerating global electricity demand and over USD 3tr in annual investment expected by 2030.



• The longevity market appears poised to capture a growing share of global profits as populations age.

Investors should focus on both leaders and laggards to capture durable and opportunistic growth.

- Investors should seek a more balanced and diversified positioning across the AI value chain, including exposure to AI laggards such as internet and software companies, and China's tech sector.
- Within power and resources, we like the electrification value chain for its exposure to growing electricity demand, data center capex, and power grid upgrades.
- In longevity, we prefer select pharma, medtech, and health-care service providers, and select companies in nutrition and wellness.

Did you know?

- Accounting firm EY projects that Europe will have more than 50 million electric vehicles (EVs) by 2030, 15% of the total vehicle stock.
- US and European firms lead in metabolic disease innovation, with the health care and wellness sectors benefiting from rising life expectancies and demographic shifts.

Investment view

Investors should consider diversified exposure to innovation leaders in AI, power infrastructure, and longevity. We see value in select technology, utilities, and health-care stocks positioned to benefit from durable, secular growth trends.

Original report - Why invest in transformational themes now?, 14 August 2025.

Disclaimer

Hong Kong / Singapore: For Global Wealth Management clients of UBS AG Singapore / Hong Kong branch, please refer to the HK/SG Marketing Material Disclaimer.

This document is prepared and published by the Global Wealth Management business of UBS Switzerland AG (regulated by FINMA in Switzerland), its subsidiaries or its affiliates ("UBS"), part of UBS Group AG ("UBS Group"). UBS Group includes former Credit Suisse AG, its subsidiaries, branches and affiliates. In the USA, UBS Financial Services Inc. is a subsidiary of UBS AG and a member of FINRA/SIPC. Additional Disclaimer relevant to Credit Suisse Wealth Management follows at the end of this section.

This document and the information contained herein are provided solely for your information and UBS marketing purposes. Nothing in this document constitutes investment research, investment advice, a sales prospectus, or an offer or solicitation to engage in any investment activities. This document is not a recommendation to buy or sell any security, investment instrument, or product, and does not recommend any specific investment program or service.

Information contained in this document has not been tailored to the specific investment objectives, personal and financial circumstances, or particular needs of any individual client. Certain investments referred to in this document may not be suitable or appropriate for all investors. In addition, certain services and products referred to in the document may be subject to legal restrictions and/or license or permission requirements and cannot therefore be offered worldwide on an unrestricted basis. No offer of any product will be made in any jurisdiction in which the offer, solicitation, or sale is not permitted, or to any person to whom it is unlawful to make such offer, solicitation, or sale.

Although all information and opinions expressed in this document were obtained in good faith from sources believed to be reliable, no representation or warranty, express or implied, is made as to the document's accuracy, sufficiency, completeness or reliability. All information and opinions expressed in this document are subject to change without notice and may differ from opinions expressed by other business areas or divisions of UBS Group. UBS is under no obligation to update or keep current the information contained herein. **The views and opinions expressed in this material by third parties are not those of UBS**. Accordingly, UBS does not accept any liability over the content shared by third parties or any claims, losses or damages arising from the use or reliance of all or any part thereof.

All pictures or images ("images") herein are for illustrative, informative or documentary purposes only and may depict objects or elements which are protected by third party copyright, trademarks and other intellectual property rights. Unless expressly stated, no relationship, association, sponsorship or endorsement is suggested or implied between UBS and these third parties.

Any charts and scenarios contained in the document are for illustrative purposes only. Some charts and/or performance figures may not be based on complete 12-month periods which may reduce their comparability and significance. Historical performance is no guarantee for, and is not an indication of future performance.

Nothing in this document constitutes legal or tax advice. UBS and its employees do not provide legal or tax advice. This document may not be redistributed or reproduced in whole or in part without the prior written permission of UBS. To the extent permitted by the law, neither UBS, nor any of it its directors, officers, employees or agents accepts or assumes any liability, responsibility or duty of care for any consequences, including any loss or damage, of you or anyone else acting, or refraining to act, in reliance on the information contained in this document or for any decision based on it.

Additional Disclaimer relevant to Credit Suisse Wealth Management: Except as otherwise specified herein and/or depending on the local entity from which you are receiving this document, this document is distributed by UBS Switzerland AG, authorised and regulated by the Swiss Financial Market Supervisory Authority (FINMA). Your personal data will be processed in accordance with the Credit Suisse privacy statement accessible at your domicile through the official Credit Suisse website https://www.credit-suisse.com. In order to provide you with marketing materials concerning our products and services, UBS Group AG and its subsidiaries may process your basic personal data (i.e. contact details such as name, e-mail address) until you notify us that you no longer wish to receive them. You can optout from receiving these materials at any time by informing your Relationship Manager.

Please visit https://www.ubs.com/global/en/wealth-management/insights/chief-investment-office/marketing-material-disclaimer.html to read the full legal disclaimer applicable to this document.

© UBS 2025. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.